Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Minnesota ,United States ,Suzhou ,Jiangsu ,Jiaotong ,Guizhou ,Xianqun ,Qinghai ,Shanghai ,American ,Chinese ,Alia Teprotumumab ,Eli Lilly ,Innovent Biologics ,Adimab Incyte ,Group Of Oculoplastic ,Group Of Thyroid Diseases ,Md Anderson Cancer Center ,Clinical Development Of Innovent ,American Thyroid Society ,Prnewswire Innovent Biologics Inc ,Chinese Ophthalmology Branch ,Chinese Academy Of Engineering ,Chinese Medical Association ,American Thyroid Association ,Development Of Medicines ,Chinese Endocrinology Branch ,China National Drug Administration ,Linkedin ,Shanghai Jiaotong University School Of Medicine ,European Group On Grave ,European Group On Grave Orbitopathy ,European Thyroid Society ,European Thyroid Association ,New Drug Application ,Drug Evaluation ,Thyroid Eye Disease ,Xianqun Fan ,Chinese Academy ,Shanghai Ninth People ,Shanghai Jiaotong University School ,Lei Qian ,Vice President ,Clinical Development ,Chinese Clinical Diagnosis ,Treatment Guidelines ,European Group ,European Thyroid ,Curr Opin ,Olmsted Country ,Trans Am Ophthalmol Soc ,Retrieved June ,Medscape Reference ,Active Thyroid Eye Disease ,Pract Res Clin Endocrinol ,Grave Orbitopathy ,Orbital Diseases ,Thyroid Diseases ,Chinese Medical ,Chinese Guidelines ,Thyroid Associated Ophthalmopathy ,Chinese Journal ,Consensus Statement ,Eur Thyroid ,